NSABP B-58
NSABP B-58
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Patient Population:
Patients with high-risk, node-positive, hormone receptor-positive, HER2-negative early-stage breast cancer
Target Accrual: 150 patients
Status: Not Recruiting
ClinicialTrials.gov Identifier: NCT03155997
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Patient Population:
Patients with high-risk, node-positive, hormone receptor-positive, HER2-negative early-stage breast cancer
Target Accrual: 150 patients
Status: Not Recruiting
ClinicialTrials.gov Identifier: NCT03155997